KaloBios to Reduce Workforce, Explore Strategic Alternatives

Go back to KaloBios to Reduce Workforce, Explore Strategic Alternatives

KaloBios Pharma (KBIO) to Cut 61% of Workforce and Explore Options

November 5, 2015 5:35 PM UTC

KaloBios Pharma (NASDAQ: KBIO) announced that it will reduce its workforce as part of a plan to reduce operating costs. This action will reduce the company's workforce by approximately 17 employees (or 61%), and will focus the company's resources on the ongoing development of lenzilumab, also known as KB003, in chronic monomyelocytic leukemia (CMML), while it continues to pursue strategic alternatives for the company.

"While this decision was extremely difficult, aligning and managing... More